Suven granted US patent for drug useful in CNS disorders

Suven Life Sciences Ltd (Suven) announced it has been granted a product Patent: No. 7,649,097 for one of its New Chemical Entities (NCE) for the treatment of disorder associated with neurodegenerative diseases. The patent will be valid until 2025.

Under the granted claims of the patent, the class of selective 5-HT compounds discovered by Suven are being developed as therapeutic agents for use in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With the new patent, Suven now has a total of five granted US product patents for its NCEs in CNS therapy. These are the exclusive intellectual property of Suven, achieved through internal drug discovery research efforts. Products out of these inventions may be out-licensed during various phases of pre-clinical and clinical development.

According to Venkat Jasti, CEO of Suven, the company was pleased to be granted the patent for its pipeline of molecules in CNS arena, that are being developed for cognitive disorders with an estimated $20 billion global market potential.